Niche unmet need Target opportunities in inner ear, middle ear, and ocular drug delivery where non-invasive magnetic delivery could overcome barriers and reduce need for invasive injections, aligning with Otomagnetics' core strengths.

Clinical progress signals Leverage preclinical success in tinnitus, noise-induced hearing loss, and chemotherapy-induced hearing loss to position partnerships around specialty neuro-otology and oncology-supportive care markets.

Strategic partnerships Explore collaborations with pharma companies seeking non-invasive delivery platforms, contract research organizations, and academic medical centers focusing on otology, ophthalmology, or drug delivery innovation.

Early-stage traction Capitalize on recent modest funding and NIH/fast-track activity to approach early-stage investors and potential licensers or co-development partners seeking novel delivery technologies.

Small team leverage With a lean team and university spin-out pedigree, pursue partnerships that provide shared risk, access to clinical and regulatory know-how, and scalable licensing or milestone-based collaborations.